source
- Curium lists Bexlutry at $63,524 per infusion, roughly 5% cheaper than Novartis' LutatheraCurium announced the list price for its radioligand Bexlutry, a generic version of Novartis' Lutathera. The price is set at $63,524 per infusion, which represents about a five percent discount com…
- Viking Therapeutics commercial chief exits after nine months; Gilead eyes BeOne executive for China growthViking Therapeutics' chief commercial officer Neil Aubuchon left the company after only nine months in the role, according to Peer Review. His brief tenure has sparked speculation about the compan…